India to Brazil: Amphotericin Export Trade Route

To import finished pharmaceutical formulations containing Amphotericin into Brazil, the following approvals and registrations are mandatory:

• Marketing Authorization (Registro): All pharmaceutical products must obtain a marketing authorization from ANVISA before commercialization. This involves submitting a comprehensive dossier that includes data on product quality, safety, and efficacy.

• Dossier Format: ANVISA accepts dossiers in the Common Technical Document (CTD) format, which should encompass modules detailing administrative information, quality aspects, non-clinical studies, and clinical studies.

• Timelines for Approval: The approval timeline can vary based on the complexity of the product and the completeness of the submitted documentation. While specific timelines are not publicly detailed, applicants should anticipate a thorough review process.

• Product Registration Fees: Fees are applicable for the registration process; however, the exact amounts are subject to periodic updates. It is advisable to consult ANVISA's official publications for the most current fee structure.

• GMP Inspection Requirements: ANVISA mandates Good Manufacturing Practice (GMP) certification for all manufacturing facilities involved in producing pharmaceutical products intended for the Brazilian market. This includes:

• On-Site Inspections: ANVISA conducts international inspections to verify compliance with GMP standards. The scheduling of these inspections is based on a risk assessment and the agency's operational capacity.

• Inspection Reports: Following an inspection, ANVISA issues a GMP certificate if the facility meets the required standards. This certificate is valid for two years from the date of publication in the Brazilian Official Gazette.

It is important to note that foreign companies cannot directly apply for product registration or GMP certification with ANVISA. They must designate a legally established partner company in Brazil to act as the local representative and assume legal responsibility for the imported products.

Indian manufacturers exporting Amphotericin formulations to Brazil must comply with the following GMP certifications and standards:

• ANVISA GMP Certification: Manufacturing facilities must obtain GMP certification from ANVISA, confirming adherence to Brazilian regulatory standards. This involves:

• Compliance with PIC/S Guidelines: As a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), ANVISA aligns its GMP requirements with internationally recognized standards.

• Regular Inspections: Facilities are subject to periodic inspections by ANVISA to ensure ongoing compliance.

Recent inspections and certifications include:

• Akums Drugs & Pharmaceuticals Ltd.: In July 2025, Akums received ANVISA GMP certification for its sterile manufacturing plant in Haridwar, Uttarakhand, enhancing its position in the Latin American injectables market.

• Naprod Life Sciences Pvt. Ltd.: In January 2026, Naprod successfully renewed its ANVISA GMP certification for its Tarapur manufacturing facility, following an inspection in July 2025 that assessed oncology injectable and oral solid dosage operations.

These certifications underscore the commitment of Indian manufacturers to maintaining high-quality standards in compliance with ANVISA regulations.

Several regulatory changes and developments between 2024 and 2026 have impacted Indian pharmaceutical exports to Brazil:

• Revised GMP Regulations in India: In January 2024, India's Ministry of Health revised its GMP regulations to align more closely with global standards, including those of the World Health Organization (WHO). The term 'Good Manufacturing Practices' was updated to 'Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products.' These changes introduced elements such as a pharmaceutical quality system (PQS), quality risk management (QRM), and product quality review (PQR), aiming to enhance the quality of drugs produced in India.

• ANVISA's Regulatory Reliance Mechanisms: In October 2024, ANVISA published Normative Instruction (IN) 289/2024, establishing optimized analysis procedures that utilize assessments conducted by Equivalent Foreign Regulatory Authorities (AREE) for the evaluation of the Letter of Suitability of the Active Pharmaceutical Ingredient (CADIFA). This initiative aims to streamline the approval process for APIs by leveraging existing evaluations from recognized regulatory bodies.

These developments reflect a concerted effort to harmonize regulatory standards and facilitate the export of high-quality pharmaceutical products between India and Brazil.

Amphotericin formulations are critical in treating severe fungal infections, particularly in immunocompromised patients. In 2024, Brazil's market for these formulations was valued at approximately $88 million USD. The demand is driven by factors such as the prevalence of fungal infections, an aging population, and increased healthcare spending. Brazil imports a significant portion of its Amphotericin formulations, with India being a notable supplier. Domestic manufacturing exists but does not fully meet the national demand, necessitating substantial imports.

Pharmaceutical imports under HS code 30049029 into Brazil are subject to an 8% MFN import duty. Additionally, a 10% Social Welfare Surcharge (SWC) is applied. Goods and Services Tax (GST) rates vary depending on the specific product and its classification. Brazil and India are both members of the World Trade Organization (WTO), but no specific Free Trade Agreement (FTA) between the two countries directly affects pharmaceutical tariffs. There are no known anti-dumping duties imposed on Amphotericin formulations imported from India.

Besides India, other major suppliers of Amphotericin formulations to Brazil include Germany, the United States, Sweden, and Switzerland. India accounts for approximately 18.88% of Brazil's total imports under HS code 30049029, indicating a significant presence in the market. Pricing dynamics are influenced by various factors, including production costs, regulatory compliance, and logistical expenses. While specific pricing data is not readily available, India's competitive manufacturing capabilities often result in cost-effective pricing compared to European manufacturers.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines. The country's pharmaceutical industry was valued at an estimated $50 billion in the fiscal year 2023-24 and is projected to reach $130 billion by 2030.

The cost-effectiveness of Indian pharmaceutical manufacturing is attributed to several factors:

• Economies of Scale: India's large-scale production capabilities allow for significant cost reductions in the manufacturing of finished dosage forms, including tablets, capsules, and injections.

• Skilled Workforce: The country boasts a highly skilled workforce, contributing to efficient and high-quality production processes.

• Regulatory Compliance: India has the highest number of USFDA-approved manufacturing facilities outside the United States, ensuring adherence to stringent international quality standards.

These advantages make India a preferred source for Amphotericin formulations globally.

When comparing Amphotericin formulation exports from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers are known for producing cost-effective generic medicines, often at lower prices than their Chinese and EU counterparts.

• Quality Perception: India's pharmaceutical industry is recognized for its high-quality standards, with numerous USFDA-approved facilities. This has bolstered the global perception of Indian pharmaceutical products.

• Regulatory Acceptance in Brazil: Indian pharmaceutical products have gained significant acceptance in Brazil, as evidenced by the substantial trade value of Amphotericin formulations exported from India to Brazil.

• Supply Reliability Track Record: India's extensive manufacturing infrastructure and experience in pharmaceutical production contribute to a reliable supply chain for Amphotericin formulations.

These factors position India favorably compared to China and the EU in terms of cost, quality, and supply reliability for Amphotericin formulations.

The India-Brazil supply chain for Amphotericin formulations demonstrates robust reliability:

• Manufacturing Capacity: India's pharmaceutical industry includes over 10,500 manufacturing facilities, enabling large-scale production of finished dosage forms.

• Packaging and Cold Chain Capabilities: Indian manufacturers have developed advanced packaging and cold chain logistics to ensure the stability and efficacy of pharmaceutical products during transit.

• Regulatory Compliance Track Record: With the highest number of USFDA-approved facilities outside the United States, Indian manufacturers consistently meet international regulatory standards.

These factors contribute to a reliable and efficient supply chain for Amphotericin formulations from India to Brazil.

For Brazilian buyers sourcing Amphotericin formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amphotericin formulations.

• Minimum Order Quantities (MOQs): Understand and negotiate MOQs with suppliers, as these can vary based on the manufacturer and the specific formulation.

• Payment Terms: Familiarize yourself with common payment terms in India-Brazil pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to facilitate smooth transactions.

• Supplier Qualification Process: Implement a thorough supplier qualification process, including audits and quality assessments, to ensure compliance with Brazilian regulatory standards and product quality requirements.

• Regulatory Compliance: Ensure that selected suppliers have the necessary certifications and approvals from relevant regulatory bodies, such as ANVISA in Brazil and CDSCO in India, to guarantee product quality and compliance.

By adopting these strategies, Brazilian buyers can effectively source high-quality Amphotericin formulations from India, ensuring both cost-effectiveness and supply reliability.

Before engaging with Indian manufacturers for Amphotericin formulations, Brazilian buyers should adhere to the following pre-qualification steps:

1. Verify ANVISA Registration: Confirm that the Amphotericin formulation is registered with ANVISA, as all pharmaceutical products require pre-market approval to be commercialized in Brazil. (gov.br)

2. Assess GMP Certification Validity: Ensure the Indian manufacturer holds a valid Good Manufacturing Practices (GMP) certificate issued by ANVISA, which is mandatory for the importation of pharmaceutical products into Brazil. (gov.br)

3. Review Drug Master File (DMF): Obtain and evaluate the DMF to verify comprehensive information on the manufacturing process, controls, and specifications of the Amphotericin formulation.

4. Evaluate Quality Management System (QMS): Confirm that the supplier has a robust QMS in place, aligning with ANVISA's GMP guidelines, to ensure consistent product quality.

5. Check Regulatory Compliance History: Investigate the manufacturer's history for any regulatory actions, such as warning letters or product recalls, which may indicate compliance issues.

6. Confirm Stability Data Availability: Ensure the manufacturer provides stability data compliant with ICH guidelines, demonstrating the product's shelf-life under various conditions.

7. Assess Export Experience: Verify the supplier's track record in exporting pharmaceutical formulations to Brazil or other Latin American markets, indicating familiarity with regional regulatory requirements.

8. Plan for Facility Audit: Schedule an on-site audit of the manufacturing facility to assess compliance with GMP standards and the adequacy of production processes.

When sourcing Amphotericin formulations from Indian manufacturers, Brazilian buyers should request the following documents:

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming it meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory purposes.

3. Good Manufacturing Practices (GMP) Certificate: Issued by ANVISA, this certificate confirms the manufacturing facility complies with GMP standards required for the Brazilian market. (gov.br)

4. Stability Data: Demonstrates the product's shelf-life and stability under various environmental conditions, in accordance with ICH guidelines.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency.

6. Drug Master File (DMF): Comprehensive information on the manufacturing process, controls, and specifications of the Amphotericin formulation.

7. Free Sale Certificate: Issued by the Central Drugs Standard Control Organization (CDSCO) in India, indicating the product is approved for sale in the Indian market.

8. Insurance Certificates: Proof of liability insurance covering potential product quality issues or recalls.

When evaluating Indian suppliers of Amphotericin formulations, be vigilant for the following warning signs:

1. Regulatory Non-Compliance: Recent warning letters from regulatory bodies or suspensions of WHO-GMP certification may indicate compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates can suggest potential compromises in quality or sourcing of substandard materials.

3. Lack of Stability Data: Inability to provide comprehensive stability data raises concerns about the product's shelf-life and efficacy.

4. Limited Export Experience: No history of exporting to Brazil or other Latin American markets may indicate unfamiliarity with regional regulatory requirements.

5. Resistance to Audits: Hesitation or refusal to allow facility audits suggests potential compliance or quality control issues.

Conducting thorough audits and continuous monitoring of Indian Amphotericin manufacturers is crucial:

1. Pre-Audit Desktop Review: Analyze submitted documents, including GMP certificates, CoAs, and DMFs, to identify potential areas of concern.

3. Post-Audit Corrective Actions: Document findings and require the manufacturer to implement corrective actions within a specified timeframe, with follow-up verification.

4. Annual Re-Qualification: Conduct yearly audits to ensure ongoing compliance with GMP standards and address any emerging issues.

5. Remote Monitoring Options: Utilize virtual audits, regular reporting, and third-party inspections to maintain oversight between on-site visits.